Burns J W & CO Inc Bristol Myers Squibb CO Transaction History

Burns J W & CO Inc

$767 Million
Q3 2024

A detailed history of Burns J W & CO Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Burns J W & CO Inc holds 33,464 shares of BMY stock, worth $1.92 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares

33,464

Previous 35,578 5.94%

Holding current value

$1.92 Million

Previous $1.48 Million 17.2%

% of portfolio

0.23%

Previous 0.2%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 04, 2024	SELL	$39.66 - $51.75 $83,841 - $109,399	-2,114 Reduced 5.94%	33,464 $1.73 Million
Q2 2024 Jul 23, 2024	SELL	$40.25 - $52.99 $197,144 - $259,545	-4,898 Reduced 12.1%	35,578 $1.48 Million
Q1 2024 Apr 17, 2024	SELL	$47.98 - $54.4 $610,017 - $691,641	-12,714 Reduced 23.9%	40,476 $2.2 Million
Q4 2023 Jan 18, 2024	SELL	$48.48 - $57.85 $100,111 - $119,460	-2,065 Reduced 3.74%	53,190 $2.73 Million
Q3 2023 Nov 13, 2023	SELL	$57.89 - $64.73 $67,731 - $75,734	-1,170 Reduced 2.07%	55,255 $3.21 Million
Q2 2023 Jul 12, 2023	SELL	$63.71 - $70.74 $29,561 - $32,823	-464 Reduced 0.82%	56,425 $3.61 Million
Q1 2023 Apr 17, 2023	BUY	$65.71 - $74.53 $3,219 - $3,651	49 Added 0.09%	56,889 $3.94 Million
Q4 2022 Jan 13, 2023	SELL	$68.48 - $81.09 $34,993 - $41,436	-511 Reduced 0.89%	56,840 $4.09 Million
Q3 2022 Oct 04, 2022	SELL	$0.13 - $76.84 $2 - $1,613	-21 Reduced 0.04%	57,351 $4.08 Million
Q2 2022 Jul 14, 2022	SELL	$72.62 - $79.98 $95,931 - $105,653	-1,321 Reduced 2.25%	57,372 $4.42 Million
Q1 2022 Apr 08, 2022	SELL	$61.48 - $73.72 $217,946 - $261,337	-3,545 Reduced 5.7%	58,693 $4.29 Million
Q4 2021 Jan 20, 2022	SELL	$53.63 - $62.52 $141,207 - $164,615	-2,633 Reduced 4.06%	62,238 $3.88 Million
Q3 2021 Oct 13, 2021	SELL	$59.17 - $69.31 $867,432 - $1.02 Million	-14,660 Reduced 18.43%	64,871 $3.84 Million
Q2 2021 Jul 12, 2021	SELL	$61.91 - $67.42 $216,437 - $235,700	-3,496 Reduced 4.21%	79,531 $5.31 Million
Q1 2021 Apr 16, 2021	SELL	$59.34 - $66.74 $269,700 - $303,333	-4,545 Reduced 5.19%	83,027 $5.24 Million
Q4 2020 Jan 12, 2021	SELL	$57.74 - $65.43 $151,336 - $171,492	-2,621 Reduced 2.91%	87,572 $5.43 Million
Q3 2020 Oct 06, 2020	SELL	$57.43 - $63.64 $296,625 - $328,700	-5,165 Reduced 5.42%	90,193 $5.44 Million
Q2 2020 Jul 06, 2020	SELL	$54.82 - $64.09 $75,706 - $88,508	-1,381 Reduced 1.43%	95,358 $5.61 Million
Q1 2020 Apr 06, 2020	SELL	$46.4 - $67.43 $124,398 - $180,779	-2,681 Reduced 2.7%	96,739 $5.39 Million
Q4 2019 Jan 07, 2020	BUY	$49.21 - $64.19 $1.73 Million - $2.26 Million	35,248 Added 54.93%	99,420 $6.38 Million
Q3 2019 Oct 11, 2019	SELL	$42.77 - $50.71 $53,761 - $63,742	-1,257 Reduced 1.92%	64,172 $3.25 Million
Q2 2019 Jul 09, 2019	SELL	$44.62 - $49.34 $126,319 - $139,681	-2,831 Reduced 4.15%	65,429 $2.97 Million
Q1 2019 Apr 02, 2019	SELL	$45.12 - $53.8 $65,243 - $77,794	-1,446 Reduced 2.07%	68,260 $3.26 Million
Q4 2018 Jan 16, 2019	SELL	$48.76 - $63.23 $175,292 - $227,311	-3,595 Reduced 4.9%	69,706 $3.62 Million
Q3 2018 Oct 05, 2018	SELL	$55.19 - $62.25 $158,671 - $178,968	-2,875 Reduced 3.77%	73,301 $4.55 Million
Q2 2018 Jul 20, 2018	SELL	$50.53 - $62.98 $3.29 Million - $4.1 Million	-65,024 Reduced 46.05%	76,176 $4.22 Million
Q1 2018 Apr 04, 2018	SELL	$59.92 - $68.98 $120,559 - $138,787	-2,012 Reduced 1.4%	141,200 $8.93 Million
Q4 2017 Jan 17, 2018	SELL	$59.94 - $65.35 $117,362 - $127,955	-1,958 Reduced 1.35%	143,212 $8.78 Million
Q3 2017 Oct 10, 2017	BUY	$55.23 - $63.74 $8.02 Million - $9.25 Million	145,170	145,170 $9.25 Million

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $122B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Burns J W & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Burns J W & CO Inc with notifications on news.

Account